Announcements Trials
Browse Landscape

Status

Available 3Approved for marketing 3No longer available 2

Sponsor Class

INDUSTRY 2

Study Type

Expanded_access 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Multiple Myeloma 20Melanoma 16Prostatic Neoplasms 15Neoplasms 15Recurrence 13Carcinoma, Non-Small-Cell Lung 13Leukemia, Myeloid, Acute 12Glioblastoma 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma 8Breast Neoplasms 7Sarcoma 6Neuroblastoma 6Lung Neoplasms 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Leukemia 6Glioma 6Pancreatic Neoplasms 5Lymphoma, Non-Hodgkin 5Lambert-Eaton Myasthenic Syndrome 5Gastrointestinal Stromal Tumors 5Colorectal Neoplasms 5Carcinoma, Hepatocellular 5Triple Negative Breast Neoplasms 4Neuroendocrine Tumors 4Liver Neoplasms 4Hodgkin Disease 4Carcinoma, Renal Cell 4Precancerous Conditions 3Pheochromocytoma 3

Interventions

rovalpituzumab tesirine 1dabrafenib 1BID protein, human 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
No longer available × Expanded_access × Small Cell Lung Carcinoma × Clear all
NCT04507919 2024-11-12

Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer

Novartis

No longer available
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

NCT03503890 2019-09-10

Expanded Access to Rovalpituzumab Tesirine

AbbVie

No longer available
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡